At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 61–70 of 483 results.
-
Researchers are doing this study to see if giving LY3537982 with standard lung cancer drugs is safe and works well. The people in this study have non-small cell lung cancer that has spread. In addition, their cancers have a gene mutation (change) called KRASG12C, which can cause cancer cells to grow.
-
Aromatase inhibitors (AIs) are medications that interfere with estrogen production and are used to reduce the risk of breast cancer recurrence in many people with breast cancer that is fueled by estrogen. One side effect of AI treatment is a decrease in bone strength, which can lead to bones becoming weak and brittle. The bones may then break (fracture) more easily.
-
Graft-versus-host disease (GVHD) is a serious condition that can happen after a stem cell transplant from a donor. The donated cells see the healthy tissues in the recipient's body as foreign and attack them. TRX103 is a new drug designed to reduce the risk of GVHD.
-
Researchers are measuring the safety of ivonescimab when given with standard lung cancer treatments and seeing how well it works. The people in this study have been newly diagnosed with squamous non-small cell lung cancer that has metastasized (spread).
-
This purpose of this study is to assess whether adding trastuzumab/hyaluronidase-oysk or pertuzumab/trastuzumab/hyaluronidase-zzxf to the usual chemotherapy (paclitaxel and carboplatin) shrinks tumors in patients with HER2-positive endometrial serous carcinoma or carcinosarcoma.
-
Isolated limb infusion (ILI) is a way to give anticancer drugs directly into an arm or leg to treat a sarcoma. However, despite this treatment, sometimes the cancer still spreads to other parts of the body. In this study, researchers want to see if adding the immunotherapy drug pembrolizumab to ILI treatment with the chemotherapy drugs melphalan and dactinomycin can help prevent the spread of cancer and increase the effectiveness of the ILI treatment in people with advanced sarcoma.
-
Researchers want to find the best dose of ETX-19477 to treat cancer. The people in this study have solid tumors that keep growing even after treatment.
-
Researchers are assessing MEDI5752 and AZD2936 with standard treatments in people with cancer. The people in this study have primary liver or biliary cancer, including biliary tract or gallbladder cancer, that spread or cannot be surgically removed (inoperable). In addition, they have not yet received treatment for the cancer.
-
The purpose of this study is to assess the safety and effectiveness of the drug mosunetuzumab for people with follicular lymphoma who have not yet received treatment. Mosunetuzumab binds to a cancer cell and a T cell (which plays a key role in the immune system) at the same time. Researchers think that mosunetuzumab may strengthen the immune system's ability to fight cancer cells by activating a patient's own cells to destroy the tumor. Mosunetuzumab is given as a subcutaneous (under the skin) injection.
-
The purpose of this study is to evaluate the safety and effectiveness of cesium-131 (Cs-131) brachytherapy in patients with brain cancer that has come back after prior radiation therapy and who will be having surgery to remove it. Brachytherapy involves the placement of radioactive seeds into the brain during surgery. The seeds remain in place permanently in the area where the tumor was removed and give off cancer-killing radiation temporarily.